A review of drug knowledge discovery using BioNLP and tensor or matrix decomposition

다국어 초록 (Multilingual Abstract)

Prediction of the relations among drug and other molecular or social entities is the main knowledge discovery pattern for the purpose of drug-related knowledge discovery. Computational approaches have combined the information from different sources and levels for drug-related knowledge discovery, which provides a sophisticated comprehension of the relationship among drugs, targets, diseases, and targeted genes, at the molecular level, or relationships among drugs, usage, side effect, safety, and user preference, at a social level. In this research, previous work from the BioNLP community and matrix or matrix decomposition was reviewed, compared, and concluded, and eventually, the BioNLP open-shared task was introduced as a promising case study representing this area.

참고문헌 (Reference)

1 Wei CH, "tmVar: a text mining approach for extracting sequence variants in biomedical literature" 29 : 1433-1439, 2013

2 Leaman R, "tmChem: a high performance approach for chemical named entity recognition and normalization" 7 : S3-, 2015

3 Hodos RA, "in silico methods for drug repurposing and pharmacology" 8 : 186-210, 2016

4 Segura-Bedmar I, "Using a shallow linguistic kernel for drug-drug interaction extraction" 44 : 789-804, 2011

5 Zhang J, "Use of genome-wide association studies for cancer research and drug repositioning" 10 : e0116477-, 2015

6 Zhang P, "Towards drug repositioning: a unified computational framework for integrating multiple aspects of drug similarity and disease similarity" 2014 : 1258-1267, 2014

7 Hitchcock FL, "The expression of a tensor or a polyadic as a sum of products" 6 : 164-189, 1927

8 Herrero-Zazo M, "The DDI corpus: an annotated corpus with pharmacological substances and drug-drug interactions" 46 : 914-920, 2013

9 Kolda TG, "Tensor decompositions and applications" 51 : 455-500, 2009

10 Su EW, "Systematic drug repositioning through mining adverse event data in ClinicalTrials.gov" 5 : e3154-, 2017

11 Sinha MS, "Social media impact of the Food and Drug Administration’s drug safety communication messaging about zolpidem: mixed-methods analysis" 4 : e1-, 2018

12 Medina-Franco JL, "Shifting from the single to the multitarget paradigm in drug discovery" 18 : 495-501, 2013

13 Segura-Bedmar I, "Semeval-2013 task 9: extraction of drug-drug interactions from biomedical texts (ddiextraction 2013)" Association for Computational Linguistics 341-350, 2013

14 Nimishakavi M, "Relation schema induction using tensor factorization with side information" Cornell University

15 Wang ZY, "Rational drug repositioning by medical genetics" 31 : 1080-1082, 2013

16 Kim JD, "Pubannotation: a persistent and sharable corpus and annotation repository" Association for Computational Linguistics 202-205, 2012

17 Wei CH, "PubTator: a web-based text mining tool for assisting biocuration" 41 : W518-W522, 2013

18 Canese K, "PubMed celebrates its 10th anniversary" 352 : e5-, 2006

19 Barupal DK, "Prioritization of metabolic genes as novel therapeutic targets in estrogen-receptor negative breast tumors using multi-omics data and text mining" 10 : 3894-3809, 2019

20 Denny JC, "PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations" 26 : 1205-1210, 2010

21 Nikfarjam A, "Pharmacovigilance from social media: mining adverse drug reaction mentions using sequence labeling with word embedding cluster features" 22 : 671-681, 2015

22 Wang L, "Personalized medicine recommendation based on tensor decomposition" 42 : 225-229, 2015

23 Chaix L, "Overview of the regulatory network of plant seed development (SeeDev) task at the BioNLP Shared Task 2016" Association for Computational Linguistics 1-11, 2016

24 Roberts K, "Overview of the TAC 2017 adverse reaction extraction from drug labels track" National Institute of Standards and Technology 2017

25 Deleger L, "Overview of the Bacteria Biotope Task at BioNLP Shared Task 2016" Association for Computational Linguistics 12-22, 2016

26 Kim JD, "Overview of genia event task in BioNLP Shared Task 2011" Association for Computational Linguistics 7-15, 2011

27 Kim JD, "Overview of BioNLP’09 Shared Task on event extraction" Association for Computational Linguistics 1-9, 2009

28 Nedellec C, "Overview of BioNLP Shared Task 2013" 1-7, 2013

29 Bourgeois FT, "Outcome reporting among drug trials registered in ClinicalTrials.gov" 153 : 158-166, 2010

30 Hamosh A, "Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders" 33 : D514-D517, 2005

31 Wang YX, "Nonnegative matrix factorization: a comprehensive review" 25 : 1336-1353, 2013

32 Ghasemi F, "Neural network and deep-learning algorithms used in QSAR studies: merits and drawbacks" 23 : 1784-1790, 2018

33 Liu Y, "Neighborhood regularized logistic matrix factorization for drug-target interaction prediction" 12 : e1004760-, 2016

34 Dai W, "Matrix factorization-based prediction of novel drug indications by integrating genomic space" 2015 : 275045-, 2015

35 Yang HT, "Literature-based discovery of new candidates for drug repurposing" 18 : 488-497, 2017

36 Ho JC, "Limestone: high-throughput candidate phenotype generation via tensor factorization" 52 : 199-211, 2014

37 Zheng J, "Learning distributed word representations and applications in biomedial natural language processing" 18 : 467-479, 1992

38 Rabanser S, "Introduction to tensor decompositions and their applications in machine learning" Cornell University

39 Taguchi YH, "Identification of candidate drugs using tensor-decomposition-based unsupervised feature extraction in integrated analysis of gene expression between diseases and DrugMatrix datasets" 7 : 13733-, 2017

40 Taguchi YH, "Identification of candidate drugs for heart failure using tensor decomposition-based unsupervised feature extraction applied to integrated analysis of gene expression between heart failure and DrugMatrix datasets" Springer 517-528, 2017

41 Arany A, "Highly scalable tensor factorization for prediction of drug-protein interaction type" Cornell University

42 Nimishakavi M, "Higher-order relation schema in- duction using tensor factorization with back-off and aggregation" Cornell University

43 Wang Y, "Guideline design of an active gene annotation corpus for the purpose of drug repurposing" Institute of Electrical and Electronics Engineers 1-5, 2018

44 Zhou KY, "GOF/LOF knowledge inference with tensor decomposition in support of high order link discovery for gene, mutation and disease" 16 : 1376-1391, 2019

45 Wei CH, "GNormPlus: an integrative approach for tagging genes, gene families, and protein domains" 2015 : 918710-, 2015

46 Banda JM, "Feasibility of prioritizing drug-drug-event associations found in electronic health records" 39 : 45-57, 2016

47 Xu J, "Extracting genetic alteration information for personalized cancer therapy from ClinicalTrials.gov" 23 : 750-757, 2016

48 Kim S, "Extracting drug-drug interactions from literature using a rich feature-based linear kernel approach" 55 : 23-30, 2015

49 Wishart DS, "DrugBank: a comprehensive resource for in silico drug discovery and exploration" 34 : D668-D672, 2006

50 Zhang M, "Drug repositioning for diabetes based on ‘omics’ data mining" 10 : e0126082-, 2015

51 Hopkins AL, "Drug discovery: predicting promiscuity" 462 : 167-168, 2009

52 Bigeard E, "Detection and analysis of drug misuses: a study based on social media messages" 9 : 791-, 2018

53 Danishuddin, "Descriptors and their selection methods in QSAR analysis: paradigm for drug design" 21 : 1291-1302, 2016

54 Habibi M, "Deep learning with word embeddings improves biomedical named entity recognition" 33 : i37-i48, 2017

55 Lee K, "Deep learning of mutation-gene-drug relations from the literature" 19 : 21-, 2018

56 Leaman R, "DNorm: disease name normalization with pairwise learning to rank" 29 : 2909-2917, 2013

57 Huang CC, "Community challenges in biomedical text mining over 10 years: success, failure and the future" 17 : 132-144, 2016

58 Zheng X, "Collaborative matrix factorization with multiple similarities for predicting drug-target interactions" Association for Computing Machinery 1025-1033, 2013

59 Dalianis H, "Clinical Text Mining: Secondary Use of Electronic Patient Records" Springer 109-148, 2018

60 Li J, "Building disease-specific drug-protein connectivity maps from molecular interaction networks and PubMed abstracts" 5 : e1000450-, 2009

61 Khan SA, "Bayesian multi-tensor factorization" 105 : 233-253, 2016

62 Lee K, "BRONCO: Biomedical entity Relation ONcology COrpus for extracting gene-variant-disease-drug relations" 2016 : baw043-, 2016

63 Barrett N, "Applying natural language processing toolkits to electronic health records: an experience report" 143 : 441-446, 2009

64 Long NP, "An integrative data mining and omics-based translational model for the identification and validation of oncogenic biomarkers of pancreatic cancer" 11 : E155-, 2019

65 Hanson CL, "An exploration of social circles and prescription drug abuse through Twitter" 15 : e189-, 2013

66 Lardon J, "Adverse drug reaction identification and extraction in social media: a scoping review" 17 : e171-, 2015

67 Nickel M, "A three-way model for collective learning on multi-relational data" Omnipress 809-816, 2011

68 Abacha AB, "A question-entailment approach to question answering" Cornell University

69 Bui QC, "A novel feature-based approach to extract drug-drug interactions from biomedical text" 30 : 3365-3371, 2014

70 Percha B, "A global network of biomedical relationships derived from text" 34 : 2614-2624, 2018

71 Demner-Fushman D, "A dataset of 200 structured product labels annotated for adverse drug reactions" 5 : 180001-, 2018

72 Fang AC, "A corpus-oriented perspective on terminologies of side effect and adverse reaction in support of text retrieval for drug repurposing" 21 : 269-286, 2018